IL271256A - Compositions and methods for treating tauopathies - Google Patents
Compositions and methods for treating tauopathiesInfo
- Publication number
- IL271256A IL271256A IL271256A IL27125619A IL271256A IL 271256 A IL271256 A IL 271256A IL 271256 A IL271256 A IL 271256A IL 27125619 A IL27125619 A IL 27125619A IL 271256 A IL271256 A IL 271256A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- treating tauopathies
- tauopathies
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/037991 WO2018231254A1 (en) | 2017-06-16 | 2017-06-16 | Compositions and methods for treating tauopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL271256A true IL271256A (en) | 2020-01-30 |
Family
ID=59388133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL271256A IL271256A (en) | 2017-06-16 | 2019-12-08 | Compositions and methods for treating tauopathies |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3638694A1 (en) |
| JP (2) | JP2020529394A (en) |
| KR (1) | KR20200018502A (en) |
| CN (1) | CN110770253A (en) |
| AU (1) | AU2017418317A1 (en) |
| BR (1) | BR112019026298A2 (en) |
| CA (1) | CA3064550A1 (en) |
| EA (1) | EA202090063A1 (en) |
| IL (1) | IL271256A (en) |
| MX (1) | MX2019015071A (en) |
| WO (1) | WO2018231254A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
| WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190261A1 (en) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | ANTIBODIES THAT RECOGNIZE TAU |
| MA47499A (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | ANTI-TAU BODIES AND THEIR METHODS OF USE |
| PE20212324A1 (en) | 2019-03-03 | 2021-12-14 | Prothena Biosciences Ltd | ANTIBODIES THAT RECOGNIZE TAU |
| JPWO2023008415A1 (en) | 2021-07-27 | 2023-02-02 | ||
| KR20230172262A (en) | 2022-06-15 | 2023-12-22 | 재단법인대구경북과학기술원 | Composition for preventing or treating tauopathy comprising PTK2 inhibitor as an active ingredient |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| ES2658596T3 (en) * | 2008-09-19 | 2018-03-12 | Pfizer Inc. | Stable liquid antibody formulation |
| WO2012049570A1 (en) * | 2010-10-11 | 2012-04-19 | Panima Pharmaceuticals Ag | Human anti-tau antibodies |
| JP5941770B2 (en) | 2012-06-28 | 2016-06-29 | 株式会社ミマキエンジニアリング | Ink jet recording apparatus, liquid supply apparatus, and recording head cleaning method |
| BR112015003326A2 (en) * | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
| EP3760228A1 (en) * | 2013-06-10 | 2021-01-06 | Ipierian, Inc. | Methods of treating a tauopathy |
| CN105899230B (en) * | 2013-11-27 | 2020-06-09 | 伊皮埃里安股份有限公司 | Methods of treating tauopathy |
| US20170247460A1 (en) * | 2014-10-18 | 2017-08-31 | Pfizer Inc. | Anti-il-7r antibody compositions |
-
2017
- 2017-06-16 AU AU2017418317A patent/AU2017418317A1/en not_active Abandoned
- 2017-06-16 JP JP2019569225A patent/JP2020529394A/en active Pending
- 2017-06-16 BR BR112019026298-9A patent/BR112019026298A2/en unknown
- 2017-06-16 WO PCT/US2017/037991 patent/WO2018231254A1/en active Application Filing
- 2017-06-16 EP EP17743107.9A patent/EP3638694A1/en not_active Withdrawn
- 2017-06-16 EA EA202090063A patent/EA202090063A1/en unknown
- 2017-06-16 CN CN201780091913.0A patent/CN110770253A/en active Pending
- 2017-06-16 MX MX2019015071A patent/MX2019015071A/en unknown
- 2017-06-16 KR KR1020197038545A patent/KR20200018502A/en not_active Application Discontinuation
- 2017-06-16 CA CA3064550A patent/CA3064550A1/en active Pending
-
2019
- 2019-12-08 IL IL271256A patent/IL271256A/en unknown
-
2021
- 2021-11-10 JP JP2021182954A patent/JP2022033757A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018231254A1 (en) | 2018-12-20 |
| MX2019015071A (en) | 2020-02-13 |
| CA3064550A1 (en) | 2018-12-20 |
| JP2020529394A (en) | 2020-10-08 |
| KR20200018502A (en) | 2020-02-19 |
| BR112019026298A2 (en) | 2020-07-14 |
| CN110770253A (en) | 2020-02-07 |
| AU2017418317A1 (en) | 2019-12-05 |
| JP2022033757A (en) | 2022-03-02 |
| EA202090063A1 (en) | 2020-04-03 |
| EP3638694A1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267247B (en) | Compositions and methods for treating cancer | |
| HK1256602A1 (en) | Compositions and methods for treating pterygium | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| IL269620A (en) | Compositions and methods for treating phenylketonuria | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| IL263460A (en) | Compositions and methods for treating cardiovascular disease | |
| IL268684A (en) | Compositions and methods for immunooncology | |
| IL274837A (en) | Methods and compositions for treating cancers | |
| PL3261644T3 (en) | Compositions and methods for treating retinal degradation | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL269637A (en) | Compositions and methods for treating synucleinopathies | |
| HK1258825A1 (en) | Methods and compositions for treating hyperhidrosis | |
| PL3402575T3 (en) | Methods and compositions for treating damaged hair | |
| IL272246A (en) | Compositions and methods for treating galactosemia | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| IL291266A (en) | Compositions and methods for treating infections | |
| HK1256541A1 (en) | Method and compositions for treating skin | |
| IL269743A (en) | Methods and compositions for treating retina-associated disease using ccr3-inhibitors | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| PL3280423T3 (en) | Synergistic glycocalyx treatment compositions and methods | |
| IL274524A (en) | Compositions and methods for aquaculturing | |
| IL271923A (en) | Methods and compositions for treating addictions |